论文部分内容阅读
肺癌中小细胞未分化癌生长速度快,倍增时间17～71日(平均33日),早期即可广泛转移。五年生存率1%以下,预后差。作者1975年11年至1980年5月,将活检及痰细胞检查诊断证实的49例中,取30例采用COM(环磷酰胺、长春新硷、甲氨喋呤)全身化疗。30例中,男性22例,女性8例,年龄40岁1例,50岁8例,60岁11例,70岁9例,90岁1例。按日本肺癌学会临床病期分类Ⅱ期2例,Ⅲ期7例,Ⅳ期21例(占70%)。治疗效果判断按肺癌学会规定,肿瘤完全消退者为显效(CR),50%以上消退者为有效(PR),肿瘤不变及50%以内消退者为不变,肿瘤增大者为恶化(PD),有效率为PR加CR而言。
Lung cancer cells with small and medium-sized undifferentiated carcinomas have a rapid growth rate. The doubling time is 17 to 71 days (mean, 33 days). The five-year survival rate is less than 1% and the prognosis is poor. From 1975 to May 1980, of the 49 cases confirmed by biopsy and sputum examination, 30 cases were treated with COM (cyclophosphamide, vinorelbine, methotrexate) systemic chemotherapy. Of the 30 cases, 22 were males and 8 were females, 1 was 40 years old, 8 was 50 years old, 11 was 60 years old, 9 was 70 years old, and 1 was 90 years old. According to the clinical stage of the Japan Lung Cancer Society, there were 2 cases in stage II, 7 cases in stage III, and 21 cases in stage IV (70%). Judgment of the therapeutic effect According to the regulations of the lung cancer society, patients with complete regression of tumors were markedly effective (CR), 50% or more of those who regressed were effective (PR), tumors remained unchanged and within 50% were subsided, and those with tumor enlargement were worsened (PD). ), the effective rate is PR plus CR.